Literature DB >> 31580184

Synaptic biomarker reduction and impaired cognition in the sub-chronic PCP mouse model for schizophrenia.

John Gigg1, Francesca McEwan1, Rebecca Smausz1, Joanna Neill2, Michael K Harte2.   

Abstract

BACKGROUND: Sub-chronic phencyclidine treatment (scPCP) provides a translational rat model for cognitive impairments associated with schizophrenia (CIAS). CIAS genetic risk factors may be more easily studied in mice; however, CIAS associated biomarker changes are relatively unstudied in the scPCP mouse. AIM: To characterize deficits in object recognition memory and synaptic markers in frontal cortex and hippocampus of the scPCP mouse.
METHODS: Female c57/bl6 mice received 10 daily injections of PCP (scPCP; 10 mg/kg, s.c.) or vehicle (n = 8/group). Mice were tested for novel object recognition memory after either remaining in the arena ('no distraction') or being removed to a holding cage ('distraction') during the inter-trial interval. Expression changes for parvalbumin (PV), glutamic acid decarboxylase (GAD67), synaptosomal-associated protein 25 (SNAP-25) and postsynaptic density 95 (PDS95) were measured in frontal cortex, dorsal and ventral hippocampus.
RESULTS: scPCP mice showed object memory deficits when distracted by removal from the arena, where they treated previously experienced objects as novel at test. scPCP significantly reduced PV expression in all regions and lower PSD95 levels in frontal cortex and ventral hippocampus. Levels of GAD67 and SNAP-25 were unchanged.
CONCLUSIONS: We show for the first time that scPCP mice: (a) can encode and retain object information, but that this memory is susceptible to distraction; (b) display amnesia after distraction; and (c) express reduced PV and PSD95 in frontal cortex and hippocampus. These data further support reductions in PV-dependent synaptic inhibition and NMDAR-dependent glutamatergic plasticity in CIAS and highlight the translational significance of the scPCP mouse.

Entities:  

Keywords:  Mouse; PSD95; novel object memory; parvalbumin; phencyclidine

Mesh:

Substances:

Year:  2019        PMID: 31580184     DOI: 10.1177/0269881119874446

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  7 in total

Review 1.  Advantages and Limitations of Animal Schizophrenia Models.

Authors:  Magdalena Białoń; Agnieszka Wąsik
Journal:  Int J Mol Sci       Date:  2022-05-25       Impact factor: 6.208

2.  Neonatal Sevoflurane Exposure Impairs Learning and Memory by the Hypermethylation of Hippocampal Synaptic Genes.

Authors:  Xin-Yu Fan; Guang Shi; Ping Zhao
Journal:  Mol Neurobiol       Date:  2020-10-14       Impact factor: 5.590

3.  Dynamic Changes of Brain Cilia Transcriptomes across the Human Lifespan.

Authors:  Siwei Chen; Wedad Alhassen; Roudabeh Vakil Monfared; Benjamin Vachirakorntong; Surya M Nauli; Pierre Baldi; Amal Alachkar
Journal:  Int J Mol Sci       Date:  2021-09-27       Impact factor: 5.923

4.  Dissociating the effects of distraction and proactive interference on object memory through tests of novelty preference.

Authors:  K Landreth; U Simanaviciute; J Fletcher; B Grayson; R A Grant; M H Harte; J Gigg
Journal:  Brain Neurosci Adv       Date:  2021-04-27

Review 5.  Imaging Synaptic Density: The Next Holy Grail of Neuroscience?

Authors:  Maria Elisa Serrano; Eugene Kim; Marija M Petrinovic; Federico Turkheimer; Diana Cash
Journal:  Front Neurosci       Date:  2022-03-25       Impact factor: 4.677

6.  Identification of Potential Key circRNAs in Aged Mice With Postoperative Delirium.

Authors:  Wei Ran; Ning Liang; Ruixue Yuan; Zhiqiao Wang; Jin Gao
Journal:  Front Mol Neurosci       Date:  2022-04-14       Impact factor: 5.639

7.  NX210c Peptide Promotes Glutamatergic Receptor-Mediated Synaptic Transmission and Signaling in the Mouse Central Nervous System.

Authors:  Sighild Lemarchant; Mélissa Sourioux; Juliette Le Douce; Alexandre Henriques; Noëlle Callizot; Sandrine Hugues; Mélissa Farinelli; Yann Godfrin
Journal:  Int J Mol Sci       Date:  2022-08-09       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.